With The Right Technology And Funding, Algae Dynamics Corp (OTCMKTS:ADYNF) Sees A Bright Future:
Algae Dynamics Corp (OTCMKTS:ADYNF) is looking at the future of microbiology culture market with hopeful eyes. However, it will take money, differentiated technology and strong execution for the company to deeply penetrate its market.
From a recent company update, it appears Algae Dynamics is making the right moves, which is why the stock is worth putting on an investor’s radar screen.
Technology
Algae Dynamics Corp (OTCMKTS:ADYNF) is still building its business upwards with no meaningful revenues or profits to cite. Nevertheless, the company remains active on the product development front. Using its proprietary BioSilo(R) technology, Algae Dynamics is creating cultivation system for microbiology culture production. The company’s product development efforts are currently pointed to creating systems for commercial growth of algae strains suitable for health and food supplement industries.
Recently, Algae Dynamics reported that its algae production facility in Mississauga, Ontario had been fully built and ready for use.
Financials
Algae Dynamics Corp (OTCMKTS:ADYNF) recently reported that it had entered a fundraiser deal with RY Capital Group, LLC that could see it secure $750,000 through equity transaction. The company is looking use the funds from equity purchase deal with RY to support its product development and working capital needs.
With adequate funding, Algae Dynamics is more flexible to innovate to strengthen its product portfolio and pipeline.
LONZA GP ZUER N AKT (OTCMKTS:LZAGF) to develop Hep C systems for Benitec:
LONZA GP ZUER N AKT (OTCMKTS:LZAGF) has been tapped by Benitec Biopharmato supply production process for the latter’s hepatitis C focused drug candidate known as TT-034. The companies have not disclosed the financial details of the deal.
In 1H2015, LONZA surpassed profit expectation as the CEO, Richard Ridinger, pledged to focus the company into more profitable businesses in the future.
Solazyme Inc (NASDAQ:SZYM) fights to avoid foul smell from Volkswagen:
Solazyme Inc (NASDAQ:SZYM) has distanced itself from claims that it was party to Volkswagen’s damaging vehicle emissions doctoring. Reports had emerged that Solazyme was among the fuel suppliers that could be tainted by Volkswagen’s emissions fiasco.
While Solazyme Inc (NASDAQ:SZYM) admits that it did test its biofuels in Volkswagen’s vehicles, it says it never certified nor backed the controversial emissions control systems.
Pricing pressure looming for Enzymotec Ltd (NASDAQ:ENZY):
Overcapacity in Enzymotec Ltd (NASDAQ:ENZY)’s industry is a serious overhang for the stock as it threatens demand and introduces pricing pressure. However, Enzymotec can leverage its largely strong financial position to mitigate adverse impact on its business, especially by protecting margins.
